Clinical trials
Withdrawn Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
92 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 8 |
| 2021 | 2 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 92 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 7 |
| Masonic Cancer Center, University of Minnesota | 5 |
| Children's Oncology Group | 3 |
| Fred Hutchinson Cancer Center | 3 |
| University of Medicine and Dentistry of New Jersey | 3 |
| Beijing Boren Hospital | 2 |
| Jazz Pharmaceuticals | 2 |
| Mayo Clinic | 2 |
| Novartis Pharmaceuticals | 2 |
| Stanford University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 92 |
| Leukemia, Myeloid, Acute | 36 |
| Leukemia | 29 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 28 |
| Burkitt Lymphoma | 27 |
| Lymphoma | 27 |
| Lymphoma, Non-Hodgkin | 27 |
| Lymphoma, Large B-Cell, Diffuse | 23 |
| Lymphoma, Mantle-Cell | 23 |
| Lymphoma, B-Cell, Marginal Zone | 22 |
Trials
Showing 51 to 75 of 92. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.